Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2019

Information on the total number of voting rights and shares

  • Read more about Information on the total number of voting rights and shares

Bone Therapeutics Reports Full Year 2019 Results

  • Read more about Bone Therapeutics Reports Full Year 2019 Results

Bone Therapeutics: Information on the total number of voting rights and shares (December 2019)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (December 2019)

Bone Therapeutics advances JTA-004 into pivotal Phase III study

  • Read more about Bone Therapeutics advances JTA-004 into pivotal Phase III study

Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development

  • Read more about Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development

Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

  • Read more about Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA

Bone Therapeutics: Information on the total number of voting rights and shares (November 2019)

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares (November 2019)

Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 12 December 2019 have been made available

  • Read more about Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 12 December 2019 have been made available

Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update

  • Read more about Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update

Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 22 November 2019 have been made available

  • Read more about Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 22 November 2019 have been made available

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2019
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions